Search Clinical Trials
Sponsor Condition of Interest |
---|
EMPOWER 3: Improving Palliative Care Health Literacy and Utilization
Tulane University
Cancer
Neoplasm Malignant
Through this award, Michael Hoerger, PhD, MSCR, a psychologist at the Tulane Cancer Center in
Louisiana, will lead a study called EMPOWER 3 designed to test an educational intervention to
help patients understand palliative care, use it, and feel better emotionally and physically.... expand
Through this award, Michael Hoerger, PhD, MSCR, a psychologist at the Tulane Cancer Center in Louisiana, will lead a study called EMPOWER 3 designed to test an educational intervention to help patients understand palliative care, use it, and feel better emotionally and physically. Participants will be adults with serious cancer diagnoses. Participants will be randomized into two groups. Patients in the control group will get enhanced usual care, meaning standard cancer care and several additional healthcare-related brochures. Patients in the intervention group will get enhanced usual care plus an educational video developed by the investigators and other materials designed to increase understanding and use of palliative care. Family members of patients in the intervention group may also attend if desired. The investigators will track participants' understanding of palliative care, attitudes toward palliative care, symptoms over 6 months of follow-up, and palliative care utilization. Type: Interventional Start Date: Mar 2021 |
A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based...
Janssen Vaccines & Prevention B.V.
Respiratory Syncytial Viruses
Lower Respiratory Tract Disease
The study will enroll up to 27,500 participants in order to demonstrate the efficacy of the
active Ad26.RSV.preF-based study vaccine in the prevention of Reverse Transcription
Polymerase Chain Reaction (RT-PCR) confirmed Respiratory Syncytial Virus (RSV)-mediated Lower
Respiratory... expand
The study will enroll up to 27,500 participants in order to demonstrate the efficacy of the active Ad26.RSV.preF-based study vaccine in the prevention of Reverse Transcription Polymerase Chain Reaction (RT-PCR) confirmed Respiratory Syncytial Virus (RSV)-mediated Lower Respiratory Tract Disease (LRTD) when compared to placebo in adults aged 60 years and above. Type: Interventional Start Date: Jul 2021 |
A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)
Syndax Pharmaceuticals
Chronic Graft-versus-host-disease
This is a Phase 2 study to evaluate the efficacy, safety, and tolerability of axatilimab at 3
different dose levels in participants with recurrent or refractory active chronic graft
versus host disease (cGVHD) who have received at least 2 prior lines of systemic therapy.
expand
This is a Phase 2 study to evaluate the efficacy, safety, and tolerability of axatilimab at 3 different dose levels in participants with recurrent or refractory active chronic graft versus host disease (cGVHD) who have received at least 2 prior lines of systemic therapy. Type: Interventional Start Date: Mar 2021 |
Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
United Therapeutics
Idiopathic Pulmonary Fibrosis
Interstitial Lung Disease
Study RIN-PF-301 is designed to evaluate the safety and efficacy of inhaled treprostinil in
subjects with idiopathic pulmonary fibrosis (IPF) over a 52-week period.
expand
Study RIN-PF-301 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with idiopathic pulmonary fibrosis (IPF) over a 52-week period. Type: Interventional Start Date: Jun 2021 |
Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH...
Galectin Therapeutics Inc.
Prevention of Esophageal Varices
NASH - Nonalcoholic Steatohepatitis
Cirrhosis
This seamless, adaptive, two-stage, Phase 2b/3, randomized, double-blind, multicenter,
parallel-groups, placebo-controlled study will assess the efficacy, safety, and tolerability
of belapectin compared with placebo in patients with nonalcoholic steatohepatitis (NASH)
cirrhosis... expand
This seamless, adaptive, two-stage, Phase 2b/3, randomized, double-blind, multicenter, parallel-groups, placebo-controlled study will assess the efficacy, safety, and tolerability of belapectin compared with placebo in patients with nonalcoholic steatohepatitis (NASH) cirrhosis and clinical signs of portal hypertension but without esophageal varices at baseline. Type: Interventional Start Date: Jun 2020 |
Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia
Janssen Research & Development, LLC
Warm Autoimmune Hemolytic Anemia
The main purpose of this study is to evaluate the efficacy and safety of M281 in participants
with warm autoimmune hemolytic anemia (wAIHA).
expand
The main purpose of this study is to evaluate the efficacy and safety of M281 in participants with warm autoimmune hemolytic anemia (wAIHA). Type: Interventional Start Date: Oct 2019 |
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
NRG Oncology
Malignant Solid Neoplasm
This trial studies how well iohexol works in helping doctors calculate the dose of
carboplatin given to patients with cancer. Drugs used in chemotherapy, such as carboplatin,
work in different ways to stop the growth of tumor cells, either by killing the cells, by
stopping... expand
This trial studies how well iohexol works in helping doctors calculate the dose of carboplatin given to patients with cancer. Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Understanding how to best calculate the dose of carboplatin given to patients with cancer may help doctors learn how to improve the use of carboplatin in the future. Type: Interventional Start Date: Nov 2019 |
Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed...
Bayer
Hemophilia A
The aim of the HEM-POWR study is to understand better how Damoctocog alfa pegol (Jivi) is
used to treat people with Hemophilia A in day-to-day life, how well the treatment is
tolerated and how satisfied patients and physicians are with the treatment.
expand
The aim of the HEM-POWR study is to understand better how Damoctocog alfa pegol (Jivi) is used to treat people with Hemophilia A in day-to-day life, how well the treatment is tolerated and how satisfied patients and physicians are with the treatment. Type: Observational Start Date: Oct 2019 |
Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular...
AbbVie
Open-Angle Glaucoma
Ocular Hypertension
This study evaluates the duration of intraocular pressure (IOP)-lowering effect and safety of
as needed administrations of Bimatoprost sustained release (SR) in participants with
open-angle glaucoma (OAG) or ocular hypertension (OHT) who are not adequately managed with
topical... expand
This study evaluates the duration of intraocular pressure (IOP)-lowering effect and safety of as needed administrations of Bimatoprost sustained release (SR) in participants with open-angle glaucoma (OAG) or ocular hypertension (OHT) who are not adequately managed with topical IOP-lowering medication for reasons other than medication efficacy. Type: Interventional Start Date: Feb 2019 |
COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial)
National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
This phase 2 clinical trial will evaluate the safety and immunogenicity of additional doses
of prototype and variant (alone or in combination) vaccine candidates in previously
vaccinated participants with or without prior severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2)... expand
This phase 2 clinical trial will evaluate the safety and immunogenicity of additional doses of prototype and variant (alone or in combination) vaccine candidates in previously vaccinated participants with or without prior severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and will evaluate innate, cellular, and humoral immune responses to inform on how to shift the immune response to cover new variants as they emerge. A randomized open-label, non-placebo controlled, multi-site, multi-stage clinical trial in individuals, 18 years of age and older, who are in a stable state of health, has received a complete authorized/approved vaccine series (primary series + booster either with homologous or heterologous vaccine products) >/ = 16 weeks prior to enrollment. Subjects will be stratified by i) age (18-64 years and >/= 65 years of age) and ii) history of confirmed prior SARS-CoV-2 infection, and randomly assigned to receive one of several variant vaccines. Enrollment will target a goal of approximately 45% of each of the variant vaccine arms to be in older adults (>/= 65 years of age) and approximately 20% to have had confirmed COVID-19.The primary objective is to evaluate humoral immune responses of candidate SARS-CoV-2 variant vaccines, alone or in combination. Type: Interventional Start Date: Mar 2022 |
A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has...
Pfizer
Multiple Myeloma
The purpose of this study is to evaluate the safety of a step-up dosing approach (starting
with low doses followed by higher doses) of the study medicine (elranatamab) in participants
with multiple myeloma that has come back after responding to treatment or has not responded... expand
The purpose of this study is to evaluate the safety of a step-up dosing approach (starting with low doses followed by higher doses) of the study medicine (elranatamab) in participants with multiple myeloma that has come back after responding to treatment or has not responded to treatment (relapsed/refractory multiple myeloma). This study will also look at the safety and efficacy of different doses of elranatamab, as well as different intervals between doses. Participants in the study will receive elranatamab as an injection under the skin at the study clinic. After the initial step-up doses, participants will start receiving one dose every week. The frequency of clinic visits for injections may then decrease over time. Participation will be at least two years. Type: Interventional Start Date: Oct 2021 |
Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal...
AVEO Pharmaceuticals, Inc.
Renal Cell Carcinoma
This study will be comparing tivozanib in combination with nivolumab to tivozanib alone in
subjects with advanced Renal Cell Carcinoma (RCC) who have had 1 or 2 prior lines of therapy,
one of which was an Immune Checkpoint Inhibitor (ICI).
expand
This study will be comparing tivozanib in combination with nivolumab to tivozanib alone in subjects with advanced Renal Cell Carcinoma (RCC) who have had 1 or 2 prior lines of therapy, one of which was an Immune Checkpoint Inhibitor (ICI). Type: Interventional Start Date: Sep 2021 |
Study to Evaluate the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician's...
Gilead Sciences
Acute Myeloid Leukemia
The primary objective of this study is to compare the efficacy of magrolimab + azacitidine
versus venetoclax + azacitidine in adults with previously untreated TP53 mutant acute myeloid
leukemia (AML) who are appropriate for non-intensive therapy as measured by overall survival... expand
The primary objective of this study is to compare the efficacy of magrolimab + azacitidine versus venetoclax + azacitidine in adults with previously untreated TP53 mutant acute myeloid leukemia (AML) who are appropriate for non-intensive therapy as measured by overall survival (OS). Type: Interventional Start Date: Jul 2021 |
Autologous Adipose-derived Stromal Vascular Fraction for Treatment of Knee Osteoarthritis
GID BIO, Inc.
Osteoarthritis, Knee
This study is a pivotal study to evaluate the efficacy and safety of a single injection of
autologous adipose-derived SVF produced using the GID SVF-2 device system for treatment of
pain with concomitant improvement in function associated with osteoarthritis of the knee
joint.... expand
This study is a pivotal study to evaluate the efficacy and safety of a single injection of autologous adipose-derived SVF produced using the GID SVF-2 device system for treatment of pain with concomitant improvement in function associated with osteoarthritis of the knee joint. Type: Interventional Start Date: Oct 2020 |
Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma
SCRI Development Innovations, LLC
Mantle Cell Lymphoma
This is a phase II study to evaluate efficacy of Acalabrutinib as a maintenance therapy
following blood or marrow transplant (BMT) in patients who have been diagnosed with mantle
cell lymphoma.
expand
This is a phase II study to evaluate efficacy of Acalabrutinib as a maintenance therapy following blood or marrow transplant (BMT) in patients who have been diagnosed with mantle cell lymphoma. Type: Interventional Start Date: Aug 2020 |
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
American Thrombosis and Hemostasis Network
Hematologic Disorder
Bleeding Disorder
Connective Tissue Disorder
Hemophilia
Thrombosis
In parallel with the growth of American Thrombosis and Hemostasis Network's (ATHN) clinical
studies, the number of new therapies for all congenital and acquired hematologic conditions,
not just those for bleeding and clotting disorders, is increasing significantly. Some of the... expand
In parallel with the growth of American Thrombosis and Hemostasis Network's (ATHN) clinical studies, the number of new therapies for all congenital and acquired hematologic conditions, not just those for bleeding and clotting disorders, is increasing significantly. Some of the recently FDA-approved therapies for congenital and acquired hematologic conditions have yet to demonstrate long-term safety and effectiveness. In addition, results from well-controlled, pivotal studies often cannot be replicated once a therapy has been approved for general use.(1,2,3,4) In 2019 alone, the United States Food and Drug Administration (FDA) has issued approvals for twenty-four new therapies for congenital and acquired hematologic conditions.(5) In addition, almost 10,000 new studies for hematologic diseases are currently registered on www.clinicaltrials.gov.(6) With this explosion of potential new therapies on the horizon, it is imperative that clinicians and clinical researchers in the field of non-neoplastic hematology have a uniform, secure, unbiased, and enduring method to collect long-term safety and efficacy data. As emphasized in a recently published review, accurate, uniform and quality national data collection is critical in clinical research, particularly for longitudinal cohort studies covering a lifetime of biologic risk.(7) The overarching objective of this longitudinal, observational study is to characterize the safety, effectiveness and practice of treatments for all people with congenital and acquired hematologic disorders in the US. Type: Observational Start Date: Sep 2020 |
Prophylactic Reinforcement of Ventral Abdominal Incisions Trial
C. R. Bard
Open Midline Laparotomy
This trial is being conducted to evaluate the efficacy of Phasix™ Mesh implantation at the
time of midline fascial closure compared to primary suture closure in preventing a subsequent
incisional hernia in subjects at risk for incisional hernia after open midline laparotomy... expand
This trial is being conducted to evaluate the efficacy of Phasix™ Mesh implantation at the time of midline fascial closure compared to primary suture closure in preventing a subsequent incisional hernia in subjects at risk for incisional hernia after open midline laparotomy surgery. Type: Interventional Start Date: Dec 2019 |
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Center for International Blood and Marrow Transplant Research
Hematologic Malignancies
Inherited Disorders of Metabolism
Inherited Abnormalities of Platelets
Histiocytic Disorders
Acute Myelogenous Leukemia (AML or ANLL)
This study is an access and distribution protocol for unlicensed cryopreserved cord blood
units (CBUs) in pediatric and adult patients with hematologic malignancies and other
indications.
expand
This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications. Type: Observational Start Date: Oct 2011 |
A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between...
ModernaTX, Inc.
SARS-CoV-2
The primary goal for this study is to evaluate up to 3 dose levels of mRNA-1273 vaccine given
to healthy children in 2 doses (in Parts 1 and 2) and 3 doses (in Part 3), and an optional
booster dose (in Parts 1 and 2).
expand
The primary goal for this study is to evaluate up to 3 dose levels of mRNA-1273 vaccine given to healthy children in 2 doses (in Parts 1 and 2) and 3 doses (in Part 3), and an optional booster dose (in Parts 1 and 2). Type: Interventional Start Date: Mar 2021 |
A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing...
Seagen Inc.
Hodgkin Lymphoma
Peripheral T Cell Lymphoma
Anaplastic Large Cell Lymphoma
This study will look at whether brentuximab vedotin works and is safe in the re-treatment
setting. To be in this study, patients must have already received brentuximab vedotin as
treatment and have cancer that progressed (got worse) after stopping treatment.
expand
This study will look at whether brentuximab vedotin works and is safe in the re-treatment setting. To be in this study, patients must have already received brentuximab vedotin as treatment and have cancer that progressed (got worse) after stopping treatment. Type: Interventional Start Date: Oct 2019 |
Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast Cancer
ECOG-ACRIN Cancer Research Group
Breast Screening
This randomized phase III trial studies digital tomosynthesis mammography and digital
mammography in screening patients for breast cancer. Screening for breast cancer with
tomosynthesis mammography may be superior to digital mammography for breast cancer screening
and may... expand
This randomized phase III trial studies digital tomosynthesis mammography and digital mammography in screening patients for breast cancer. Screening for breast cancer with tomosynthesis mammography may be superior to digital mammography for breast cancer screening and may help reduce the need for additional imaging or treatment. Type: Interventional Start Date: Jul 2017 |
Medication Adherence Program
Tulane University
Hypertension
Medication Adherence
Behavior and Behavior Mechanisms
Randomized controlled trial testing the efficacy of the Supporting Tailored Adaptive change
and Reinforcement for Medication Adherence Program (STAR-MAP), a health coaching approach
that aims to improve antihypertensive medication adherence, blood pressure control, and
quality... expand
Randomized controlled trial testing the efficacy of the Supporting Tailored Adaptive change and Reinforcement for Medication Adherence Program (STAR-MAP), a health coaching approach that aims to improve antihypertensive medication adherence, blood pressure control, and quality of life. Participants (n=402) >=55 years old with a diagnosis of hypertension, uncontrolled blood pressure, and low antihypertensive medication adherence will be recruited through a statewide health insurer, Blue Cross Blue Shield of Louisiana, and randomized to receive either interactive health coaching sessions with medication reminder tools (intervention) or medication reminder tools only (control) over one year. Data will be collected from participants at baseline, 6 months, 12 months, and 24 months using questionnaires, physical measurement (height, weight, blood pressure), a computer-based single-category implicit association test, and laboratory analysis of antihypertensive medication urinary metabolites. Type: Interventional Start Date: Mar 2022 |
Prospective Global Registry for the Study of Chronic Total Occlusion Intervention
Minneapolis Heart Institute Foundation
Coronary Artery Disease
Percutaneous coronary intervention (PCI) of chronic total occlusions (CTOs) is increasingly
being performed in patients with advanced coronary artery disease, but there is limited
information on the techniques utilized and the procedural outcomes. The goal of this
multicenter,... expand
Percutaneous coronary intervention (PCI) of chronic total occlusions (CTOs) is increasingly being performed in patients with advanced coronary artery disease, but there is limited information on the techniques utilized and the procedural outcomes. The goal of this multicenter, investigator initiated registry is to collect information on treatment strategies and outcomes of consecutive patients undergoing CTO PCI among various participating centers. The information collected will be used to determine the frequency of CTO PCI performed at the participating sites and examine the procedural strategies utilized, and the procedural (both immediate and during follow-up) outcomes. Type: Observational [Patient Registry] Start Date: Jan 2012 |
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors,...
National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm
Bladder Carcinoma
Breast Carcinoma
Cervical Carcinoma
Colon Carcinoma
This phase II MATCH trial studies how well treatment that is directed by genetic testing
works in patients with solid tumors or lymphomas that have progressed following at least one
line of standard treatment or for which no agreed upon treatment approach exists. Genetic
tests... expand
This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma. Type: Interventional Start Date: Aug 2015 |
Integrated Cancer Repository for Cancer Research
University of Nebraska
Pancreatic Cancer
Thyroid Cancer
Lung Cancer
Esophageal Cancer
Thymus Cancer
The iCaRe2 is a multi-institutional resource created and maintained by the Fred & Pamela
Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal
data and biospecimens on consented adult cancer patients, high-risk individuals, and normal
controls.... expand
The iCaRe2 is a multi-institutional resource created and maintained by the Fred & Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer development and progression and enables the design of novel strategies for prevention, screening, early detection and personalized treatment of cancer. Centers with expertise in cancer epidemiology, genetics, biology, early detection, and patient care can collaborate by using the iCaRe2 as a platform for cohort and population studies. Type: Observational [Patient Registry] Start Date: Nov 2013 |